This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawakami, Y.
Right arrow Articles by Katsuyama, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawakami, Y.
Right arrow Articles by Katsuyama, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2000, p. 458-461, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials against Recent Clinical Isolates of Helicobacter pylori

Yoshiyuki Kawakami,1,* Takayuki Akahane,2,dagger Masaru Yamaguchi,2 Kozue Oana,1 Yuko Takahashi,2 Yukie Okimura,2 Tadashi Okabe,2 Akira Gotoh,3,Dagger and Tsutomu Katsuyama4

Division of Clinical Microbiology, Department of Medical Technology, School of Allied Medical Sciences, Shinshu University,1 Central Clinical Laboratories, Shinshu University Hospital,2 and The Second Department of Internal Medicine,3 and Department of Laboratory Medicine,4 Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan

Received 17 May 1999/Returned for modification 24 August 1999/Accepted 15 November 1999

The MICs of rabeprazole sodium (RPZ), a newly developed benzimidazole proton pump inhibitor (PPI), against 133 clinical Helicobacter pylori strains revealed a higher degree of activity than the another two PPIs, lansoprazole and omeprazole. Time-kill curve assays of RPZ, when combined with amoxicillin, clarithromycin, or metronidazole, disclosed that synergistic effects were demonstrated in combination with each antibiotic examined. Moreover, no apparent antagonistic effect appeared among all of the strains tested.

* Corresponding author. Mailing address: Division of Clinical Microbiology, Department of Medical Technology, School of Allied Medical Sciences, Shinshu University, Matsumoto, 390-8621, Japan. Phone: 81-263-37-2381. Fax: 81-263-37-2370. E-mail: yk23724{at}gipac.shinshu-u.ac.jp.

dagger Present address: Central Clinical Laboratories, Toyoshina Red Cross Hospital, Toyoshina, 399-8292, Japan.

Dagger Present address: Department of Internal Medicine, Nagano Municipal Hospital, Nagano, 381-8551, Japan.

Antimicrobial Agents and Chemotherapy, February 2000, p. 458-461, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»